Role of M6a Methylation in Myocardial Ischemia–Reperfusion Injury and Doxorubicin-Induced Cardiotoxicity
Authors:
- 18 July 2024
- journal article
- review article
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 24 (9) , 918-928
Abstract
Cardiovascular disease remains the leading cause of death worldwide, with acute myocardial infarction and anticancer drug-induced cardiotoxicity being the significant factors. The most effective treatment for acute myocardial infarction is rapid restoration of coronary blood flow by thrombolytic therapy or percutaneous coronary intervention. However, myocardial ischemia–reperfusion injury (MI/RI) after reperfusion therapy is common in acute myocardial infarction, thus affecting the prognosis of patients with acute myocardial infarction. There is no effective treatment for MI/RI. Anthracyclines such as Doxorubicin (DOX) have limited clinical use due to their cardiotoxicity, and the mechanism of DOX-induced cardiac injury is complex and not yet fully understood. N6-methyladenosine (m6A) plays a crucial role in many biological processes. Emerging evidence suggests that m6A methylation plays a critical regulatory role in MI/RI and DOX-induced cardiotoxicity (DIC), suggesting that m6A may serve as a novel biomarker and therapeutic target for MI/RI and DIC. M6A methylation may mediate the pathophysiological processes of MI/RI and DIC by regulating cellular autophagy, apoptosis, oxidative stress, and inflammatory response. In this paper, we first focus on the relationship between m6A methylation and MI/RI, then further elucidate that m6A methylation may mediate the pathophysiological process of MI/RI through the regulation of cellular autophagy, apoptosis, oxidative stress, and inflammatory response. Finally, briefly outline the roles played by m6A in DIC, which will provide a new methodology and direction for the research and treatment of MI/RI and DIC.Keywords
Funding Information
- National Natural Science Foundation of China (82170260)
This publication has 79 references indexed in Scilit:
- Targeting non-coding RNAs and N6-methyladenosine modification in hepatocellular carcinomaBiochemical Pharmacology, 2024
- Toll-like receptor 4 (TLR4) inhibitors: Current research and prospectiveEuropean Journal of Medicinal Chemistry, 2022
- METTL14 promotes doxorubicin-induced cardiomyocyte ferroptosis by regulating the KCNQ1OT1-miR-7-5p-TFRC axisCell Biology and Toxicology, 2021
- The Role of Non-coding RNAs in Ischemic Myocardial Reperfusion InjuryCardiovascular Drugs and Therapy, 2019
- mTOR and Beclin1: Two key autophagy‐related molecules and their roles in myocardial ischemia/reperfusion injuryJournal of Cellular Physiology, 2019
- Comprehensive Analysis of mRNA Methylation Reveals Enrichment in 3′ UTRs and near Stop CodonsCell, 2012
- Pathology of late-onset anthracycline cardiomyopathyCardiovascular Pathology, 2010
- Pathogenesis of Myocardial Ischemia-Reperfusion Injury and Rationale for TherapyThe American Journal of Cardiology, 2010
- Protective effects of N-acetylcysteine in isoproterenol-induced myocardium injury in ratsMolecular Biology Reports, 2008
- Nitric oxide: inhibitory effects on endothelial cell calcium signaling, prostaglandin I2 production and nitric oxide synthase expressionCardiovascular Research, 2004